New Risk • Aug 04
New major risk - Financial position The company has less than a year of cash runway based on its current free cash flow trend. Free cash flow: -US$15m This is considered a major risk. With less than a year's worth of cash, the company will need to raise capital or take on debt unless its cash flows improve. This would dilute existing shareholders or increase balance sheet risk. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-US$15m free cash flow). Earnings are forecast to decline by an average of 21% per year for the foreseeable future. Shareholders have been substantially diluted in the past year (218% increase in shares outstanding). Revenue is less than US$1m. Market cap is less than US$10m (US$5.26m market cap). Minor Risks Currently unprofitable and not forecast to become profitable over next 3 years (US$38m net loss in 3 years). Share price has been volatile over the past 3 months (13% average weekly change). Announcement • Jul 27
FibroBiologics, Inc. Receives Nasdaq Delisting Notice for Common Stock On July 22, 2026, FibroBiologics, Inc. received a Staff Determination letter (the Staff Determination) from the Listing Qualifications Department of The Nasdaq Stock Market LLC (Nasdaq) notifying the Company that Nasdaq Staff had determined to delist the Company's securities from The Nasdaq Capital Market. The Staff Determination stated that the bid price of the Company's listed securities had closed at less than $1.00 per share over the previous 30 consecutive business days, from June 8, 2026 through July 21, 2026, and that, as a result, the Company is not in compliance with Nasdaq Listing Rule 5550(a)(2), which requires listed securities to maintain a minimum bid price of $1.00 per share (the Bid Price Rule). The Staff Determination further stated that, although companies are normally afforded a 180-calendar day period to demonstrate compliance with the Bid Price Rule, the Company is not eligible for any such compliance period pursuant to Nasdaq Listing Rule 5810(c)(3)(A)(iv) due to the fact that the Company has effected a reverse stock split over the prior one-year period. Unless the Company requests an appeal of this determination by July 29, 2026, Nasdaq staff has determined that the Company's securities will be scheduled for delisting from The Nasdaq Capital Market and will be suspended at the opening of business on July 31, 2026. The Company intends to timely request a hearing before a Nasdaq Hearings Panel (the Panel) to appeal Nasdaq Staff's determination. A timely hearing request will stay any further delisting actions through the hearing process. At the hearing, the Company expects to present its plan to regain compliance with Nasdaq's continued listing requirements. There can be no assurance that the Company will be successful in its appeal, that the Panel will grant the Company's request for continued listing, or that the Company will be able to regain or maintain compliance with any applicable Nasdaq listing requirements. The Company intends to actively monitor the closing bid price of its common stock and evaluate all available options to regain compliance with the Bid Price Rule. Announcement • Jul 10
FibroBiologics, Inc. Announces the Resignation of Matt Link from the Board of Directors, Effective July 2, 2026 FibroBiologics, Inc. announced that on July 2, 2026, Matt Link notified the company that he was resigning from the Board of Directors, effective as of July 2, 2026. 
